A recent study by a research department at the Japan Pharmaceutical Manufacturer Association (JPMA) outlines how many Japanese and foreign drug companies are not increasing (and in some cases decreasing) their investment and focus in Japan’s drug market. One of the many reasons for this is drug price reductions over the years. While Japan has generally implemented price cuts every two years, there have been annual off-year reductions over the last few years.
Given the situation above, the MHLW is now discussing limiting price reductions for 2023. Industry has claimed that lower prices reduce investment, the initiation of new drugs, and can cause supply shortages.
Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.
Source used in the article: https://www.pharmaceutical-technology.com/pricing-and-market-access/japanese-pharmaceutical-market-lenient-price-controls/